JP2022515248A5 - - Google Patents
Info
- Publication number
- JP2022515248A5 JP2022515248A5 JP2021536402A JP2021536402A JP2022515248A5 JP 2022515248 A5 JP2022515248 A5 JP 2022515248A5 JP 2021536402 A JP2021536402 A JP 2021536402A JP 2021536402 A JP2021536402 A JP 2021536402A JP 2022515248 A5 JP2022515248 A5 JP 2022515248A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition according
- pharmaceutical composition
- group
- myeloid leukemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862783741P | 2018-12-21 | 2018-12-21 | |
| US62/783,741 | 2018-12-21 | ||
| PCT/CA2019/051884 WO2020124262A1 (en) | 2018-12-21 | 2019-12-20 | New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022515248A JP2022515248A (ja) | 2022-02-17 |
| JP2022515248A5 true JP2022515248A5 (https=) | 2022-12-28 |
Family
ID=71100034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021536402A Pending JP2022515248A (ja) | 2018-12-21 | 2019-12-20 | 新規なサリチル酸誘導体、その医薬的に許容される塩、その組成物及びその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220089531A1 (https=) |
| EP (1) | EP3898582A4 (https=) |
| JP (1) | JP2022515248A (https=) |
| CN (1) | CN113661158A (https=) |
| CA (1) | CA3124267A1 (https=) |
| WO (1) | WO2020124262A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3174623A1 (en) * | 2020-03-05 | 2021-09-10 | Janpix, Ltd. | Stat inhibitory compounds and compositions |
| EP4114371A4 (en) * | 2020-03-05 | 2024-04-17 | Centessa Pharmaceuticals (UK) Limited | ALPHA-SUBSTITUTED STAT INHIBITORS AND COMPOSITIONS THEREOF |
| TW202227398A (zh) * | 2020-09-04 | 2022-07-16 | 英商詹皮克斯有限公司 | Stat抑制性化合物及組合物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007136858A2 (en) * | 2006-05-19 | 2007-11-29 | H. Lee Moffitt Cancer Center & Research Institute | Small molecule inhibitors of stat3 with anti-tumor activity |
| CN103608010A (zh) * | 2010-08-02 | 2014-02-26 | 中央佛罗里达大学研究基金公司 | 作为stat蛋白的抑制剂的取代的2-羟基-4-(2-(苯基磺酰氨基)乙酰氨基)苯甲酸类似物 |
| CN102219755B (zh) * | 2011-05-05 | 2013-04-03 | 南京大学 | Stat3的小分子选择性抑制剂及其制备方法和应用 |
| CN110003104A (zh) * | 2012-05-25 | 2019-07-12 | 多伦多大学管理委员会 | 水杨酸衍生物、其药学上可接受的盐、其组合物以及其使用方法 |
| WO2014070859A1 (en) * | 2012-10-30 | 2014-05-08 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Stat3 dimerization inhibitors |
| BR112016028022B1 (pt) * | 2014-05-30 | 2023-03-28 | The Governing Council Of The University Of Toronto | Compostos de sulfonamida inibidores de stat5 |
-
2019
- 2019-12-20 EP EP19901001.8A patent/EP3898582A4/en not_active Withdrawn
- 2019-12-20 WO PCT/CA2019/051884 patent/WO2020124262A1/en not_active Ceased
- 2019-12-20 JP JP2021536402A patent/JP2022515248A/ja active Pending
- 2019-12-20 CA CA3124267A patent/CA3124267A1/en active Pending
- 2019-12-20 CN CN201980089744.6A patent/CN113661158A/zh active Pending
- 2019-12-20 US US17/416,175 patent/US20220089531A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9856218B2 (en) | Inhibitors of PRMT5 and methods of their use | |
| JP2022515248A5 (https=) | ||
| WO2020150417A3 (en) | Compounds and compositions for treating conditions associated with sting activity | |
| EP4699660A3 (en) | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders | |
| JP2009534408A5 (https=) | ||
| RU2013131004A (ru) | Комбинация (а) ингибитора фосфоинозит-3-киназы и (б) модулятора пути ras/raf/mek | |
| JP2010532768A5 (https=) | ||
| JP2006523216A5 (https=) | ||
| JP2015520753A5 (https=) | ||
| US10183035B2 (en) | Etoposide and prodrugs thereof for use in targeting cancer stem cells | |
| RS20230516A1 (sr) | Postupci za lečenje raka prostate | |
| JP2018525441A5 (https=) | ||
| JP2015512943A5 (https=) | ||
| JP2008535902A5 (https=) | ||
| JP2011510014A5 (https=) | ||
| JP2021530453A5 (https=) | ||
| JP2021525768A5 (https=) | ||
| US9833431B2 (en) | Pharmaceutical combinations for the treatment of cancer | |
| JP2025504379A5 (https=) | ||
| MX2022014192A (es) | Metodos para tratar el cancer de prostata. | |
| JP2009506054A5 (https=) | ||
| EA200800516A1 (ru) | Производные n-фенил-2-пиримидинамина и процесс их получения | |
| RU2020111019A (ru) | Полиморфная форма tg02 | |
| JP2013544892A5 (https=) | ||
| JP2022527916A (ja) | アンドロゲン受容体のｎ末端ドメインの阻害剤 |